These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33037234)

  • 21. Characterization of
    Watanabe H; Inoue Y; Karayama M; Yazawa S; Mochizuka Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Shinmura K; Inui N; Suda T
    JCO Precis Oncol; 2024 Apr; 8():e2300538. PubMed ID: 38662982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review.
    Shimada Y; Sato Y; Tachikawa R; Hara S; Tomii K
    Invest New Drugs; 2021 Dec; 39(6):1702-1706. PubMed ID: 34023984
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
    Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dabrafenib and trametinib for the treatment of non-small cell lung cancer.
    Kelly RJ
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1063-1068. PubMed ID: 30198802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges of targeting
    Smith-Cohn M; Davidson C; Colman H; Cohen AL
    CNS Oncol; 2019 Dec; 8(4):CNS48. PubMed ID: 31818130
    [No Abstract]   [Full Text] [Related]  

  • 30. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
    Jiang L; Yang P; Liu Y; Li J
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
    White PS; Pudusseri A; Lee SL; Eton O
    Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.
    Inoue T; Kunimasa K; Tamiya M; Kawamura T; Minami T; Nishino K
    Thorac Cancer; 2024 Apr; 15(11):929-933. PubMed ID: 38429896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response of BRAF
    Yamamoto G; Sakakibara-Konishi J; Ikari T; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
    J Thorac Oncol; 2019 May; 14(5):e97-e99. PubMed ID: 31027751
    [No Abstract]   [Full Text] [Related]  

  • 35. Dabrafenib-trametinib combination therapy re-challenge in advanced BRAF
    Kashizaki F; Tanaka A; Hattori S; Sugimoto S
    Eur J Cancer; 2021 Jan; 143():31-32. PubMed ID: 33278771
    [No Abstract]   [Full Text] [Related]  

  • 36. Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma.
    Ichikawa K; Ohno S; Kubo S; Nakajima H
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF.
    Seto K; Haneda M; Masago K; Fujita S; Kato S; Sasaki E; Hosoda W; Murakami Y; Kuroda H; Horio Y; Hida T; Okubo K; Yatabe Y
    Pathol Int; 2020 May; 70(5):253-261. PubMed ID: 31970865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report.
    Pan J
    Clin Drug Investig; 2019 Oct; 39(10):1003-1007. PubMed ID: 31250402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
    Li J; Sasane M; Zhang J; Zhao J; Ricculli ML; Yao Z; Redhu S; Signorovitch J
    BMJ Open; 2018 Aug; 8(8):e021642. PubMed ID: 30121602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.